Sandoz launches KERYDIN TM (tavaborole) topical solution, 5% from Anacor Pharmaceuticals, Inc.
`
`ABOUT US
`
`OUR PRODUCTS
`
`CAREERS
`
`CORPORATE RESPONSIBILITY
`
`MEDIA CENTER
`
`Home
`
`Media Center
`
`Global News
`
`MEDIA CENTER
`
`TEXT SIZE | PRINTER FRIENDLY | RSS FEEDS
`
`FREQUENTLY ASKED
`QUESTIONS
`
`Everything you wanted to know
`about the generics industry.
`More
`
`SUBSCRIBE TO NEWS
`UPDATES
`
`Please click here if you would
`like to receive regular news
`and press releases.
`
`MEDIA CENTER
`
`PRESS RELEASES &
`NEWS
`
`FACTS & FIGURES
`
`PUBLICATIONS
`
`MULTIMEDIA GALLERY
`
`MEDIA CONTACTS
`
`SUBSCRIBE TO NEWS
`
`SANDOZ LAUNCHES KERYDIN TM
`(TAVABOROLE) TOPICAL SOLUTION, 5%
`FROM ANACOR PHARMACEUTICALS,
`INC.
`Princeton, New Jersey, September 22, 2014 - Sandoz, through its
`branded dermatology business, PharmaDerm, today announced the US
`launch of KERYDINTM (tavaborole) topical solution, 5%, developed by
`Anacor Pharmaceuticals, Inc.
`
`In July 2014, Sandoz announced an agreement with Anacor
`Pharmaceuticals, Inc. to obtain exclusive rights to commercialize
`KERYDINTM in the US.
`
`KERYDINTM is the first oxaborole antifungal indicated for the topical
`treatment of onychomycosis of the toenails due to Trichophyton rubrum
`or Trichophyton mentagrophytes, a fungal infection of the nail and nail
`bed that affects approximately 35 million people in the US, according to
`Podiatry Today.
`
`“KERYDIN TM is an important product to PharmaDerm’s portfolio and
`helps to reinforce our leadership in the topical dermatology specialty
`market,” said Peter Goldschmidt, President of Sandoz Inc.
`
`Disclaimer
`
`The foregoing release contains forward-looking statements that can be
`identified by words such as “launches,” “introduction,” “launch,” “will,” or
`similar terms, or by express or implied discussions regarding potential
`future product approvals, or regarding potential revenues from
`KERYDINTM (tavaborole) topical solution, 5% or any potential future
`products. You should not place undue reliance on these statements.
`Such forward-looking statements are based on the current beliefs and
`expectations of management regarding future events, and are subject
`
`http://www.es.sandoz.com/media_center/press_releases_news/global_news/2014_09_23_kerydin.shtml[10/31/2017 7:34:21 AM]
`
`ACRUX DDS PTY LTD. et al.
`
`EXHIBIT 1605
`
`IPR Petition for
`
`U.S. Patent No. 7,214,506
`
`Page 1 of 3
`
`

`

`Sandoz launches KERYDIN TM (tavaborole) topical solution, 5% from Anacor Pharmaceuticals, Inc.
`
`to significant known and unknown risks and uncertainties. Should one
`or more of these risks or uncertainties materialize, or should underlying
`assumptions prove incorrect, actual results may vary materially from
`those set forth in the forward-looking statements. There can be no
`guarantee that any potential new products will receive regulatory
`approval in the future, or that KERYDINTM (tavaborole) topical solution,
`5%or any such potential new products will be commercially successful
`in the future. In particular, management’s expectations could be
`affected by, among other things, unexpected regulatory actions or
`delays or government regulation generally; competition in general,
`including potential approval of additional versions of KERYDINTM
`(tavaborole) topical solution, 5%; government, industry and general
`public pricing pressures; unexpected patent litigation outcomes;
`unexpected manufacturing issues; general economic and industry
`conditions, and other risks and factors referred to in Novartis AG’s
`current Form 20-F on file with the US Securities and Exchange
`Commission. Novartis is providing the information in this press release
`as of this date and does not undertake any obligation to update any
`forward-looking statements contained in this press release as a result of
`new information, future events or otherwise.
`
`About Sandoz
`
`Sandoz, the generic pharmaceuticals division of Novartis, is a global
`leader in the generic pharmaceutical sector. Sandoz employs over
`26,500 employees across more than 160 countries, offering a broad
`range of high-quality, affordable products that are no longer protected
`by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio
`of approximately 1,100 molecules, and holds the #1 position globally in
`biosimilars as well as in generic injectables, ophthalmics, dermatology
`and antibiotics, complemented by leading positions in the
`cardiovascular, metabolism, central nervous system, pain,
`gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz
`develops, produces, and markets these medicines, as well as active
`pharmaceutical and biotechnological substances. Nearly half of
`Sandoz's portfolio is in differentiated products, which are defined as
`products that are more difficult to scientifically develop and manufacture
`than standard generics. In addition to strong organic growth since
`consolidating its generics businesses under the Sandoz brand name in
`2003, Sandoz has benefitted from strong growth of its acquisitions,
`which include Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon
`Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and
`Fougera Pharmaceuticals (US).
`
`* * *
`For further information
`Sandoz US Communications
`Leslie Pott
`+1 609 627 5287
`leslie.pott@sandoz.com
`
`Sandoz Global Communications
`Neil Moorhouse
`+49 8024 476 2597
`neil.moorhouse@sandoz.com
`
`http://www.es.sandoz.com/media_center/press_releases_news/global_news/2014_09_23_kerydin.shtml[10/31/2017 7:34:21 AM]
`
`Page 2 of 3
`
`

`

`Sandoz launches KERYDIN TM (tavaborole) topical solution, 5% from Anacor Pharmaceuticals, Inc.
`
`Footnotes:
`1 For full safety information, please see the KERYDINTM (tavaborole)
`topical solution, 5%, prescribing information, available in the Product
`Catalog at www.us.sandoz.com.
`2 KERYDIN is a trademark of Anacor Pharmaceuticals, Inc.
`
`SANDOZ WORLDWIDE
`
`RECENTLY ON TWITTER
`
`FOLLOW US ON
`
`Sandoz Websites:
`
`You are on the website of Sandoz
`International. Please select from the
`above dropdown to visit a local
`website.
`
`Contact us
`
`Sitemap
`
`Terms of use
`
`Privacy Policy
`
`Report an Adverse Event
`
`Legal Notice
`
`© Sandoz 2010 – 2016
`
`a Novartis company
`
`http://www.es.sandoz.com/media_center/press_releases_news/global_news/2014_09_23_kerydin.shtml[10/31/2017 7:34:21 AM]
`
`Sandoz Websites:
`
`Page 3 of 3
`
`